Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cintredekin besudotox

Drug Profile

Cintredekin besudotox

Alternative Names: hIL13-PE38QQR; IL13-PE38; IL13-PE38QQR; Interleukin-13-PE38QQR immunotoxin; NK 408

Latest Information Update: 17 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer INSYS Therapeutics, Inc; National Institutes of Health (USA); Nippon Kayaku
  • Class Antineoplastics; Exotoxins; Immunotoxins; Interleukins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anaplastic astrocytoma; Idiopathic pulmonary fibrosis; Glioblastoma; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adrenocortical carcinoma; Asthma; Glioma; Pulmonary fibrosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Nov 2014 Insys Therapeutics terminates a phase I/II trial in Adrenocortical carcinoma (metastatic disease, second-line therapy or greater) in USA (NCT01832974)
  • 01 Jul 2011 Insys Therapeutics completes a phase I trial in Malignant glioma (newly diagnosed) in USA (NCT00089427)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top